BCG vaccine-induced protection from COVID-19 infection, wishful thinking or a game changer?

Luis E. Escobar[1], Alvaro Molina-Cruz[2] and Carolina Barillas-Mury[2]

[1] Department of Fish and Wildlife Conservation, Virginia Tech, Blacksburg, VA, USA

[2]Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health (NIH), Rockville, MD, USA

*** Correspondence:** cbarillas@niaid.nih.gov and escobar1@vt.edu

Abstract

A series of epidemiological explorations have suggested a negative association between national BCG vaccination policy and the prevalence and mortality of COVID-19. Nevertheless, these comparisons are difficult to validate due to broad differences between countries such as socioeconomic status, demographic structure, rural vs. urban settings, time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national control strategies to limit the spread of COVID-19. We review evidence for the potential biological basis of BCG cross-protection from severe COVID-19 and refine the epidemiological analysis to mitigate effects of potentially confounding factors (e.g., stage of the COVID-19 epidemic, development, rurality, population density and age structure). Results fail to confirm the null hypothesis of no-association between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective effect. Nevertheless, the analyses are restricted to coarse-scale signals and should be considered with caution. BCG vaccination clinical trials are required to corroborate the patterns detected here and to establish causality between BCG vaccination and protection from severe COVID-19. Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed.

Keywords
BCG vaccination, COVID-19, Cross-protection, Mortality, Pandemic, Policy.

Significance Statement

The COVID-19 pandemic is one of the most devastating in recent history. The bacillus Calmette-Guérin (BCG) vaccine against tuberculosis also confers broad protection against other infectious diseases, and it has been proposed that it could reduce the severity of COVID-19. This epidemiological study assessed the global linkage between BCG vaccination and COVID-19 mortality. Signals of BCG effect on COVID-19 mortality are influenced by social, economic, and demographic differences between countries. After mitigating multiple confounding factors, several significant associations between BCG vaccination and reduced COVID-19 deaths were observed. This study highlights the need for mechanistic studies behind the effect of BCG vaccination on COVID-19, and for clinical evaluation of the effectiveness of BCG vaccination to protect from severe COVID-19.

Introduction

Classic pathogen-specific immunity *vs* broad-protection through innate immune training

The innate immune system is the first line of defense against invading pathogens and involves several players, including immune cells such as monocytes, γδ T cells, natural killer (NK) cells, macrophages, and dendritic cells (1). Immune cells constantly patrol the different organs, especially the gastrointestinal tract, airways, and the lungs, which have direct contact with the environment. Inhaled pathogens can multiply in the upper respiratory tract and, if not properly contained, infections can spread to the lower respiratory tract and the lungs. Upon encountering a pathogen, antigen presenting cells process fragments of the microbe and direct the adaptive immune system to activate the appropriate type of defense response (1).

There are two major types of adaptive immune responses to specific pathogens that confer immunological memory and can be stimulated through vaccination: humoral and cellular. The humoral or antibody-mediated immune response involves the production of high antibody titers that bind to the surface of pathogens circulating outside the cells and neutralize or label them for destruction. A different system is required for intracellular pathogens that

cannot be reached by antibodies. The cellular immune response involves the proliferation and differentiation of T-lymphocytes into cytotoxic T-cells that identify and destroy infected cells, or activation of macrophages to destroy microorganisms they have ingested.

Cellular immunity is very important to control infections by intracellular pathogens, such as *Mycobacterium (M.) tuberculosis,* responsible for tuberculosis disease (TB) in humans (2). Gamma interferon (γ-IFN) is a key cytokine produced by CD4+ T-cells that mediates macrophage activation and resistance to *M. tuberculosis* (2). Enhanced susceptibility to TB is seen in humans with mutations in the γ-IFN receptor (3) and in mice in which the γ-IFN gene has been disrupted (4).

The bacillus Calmette-Guérin (BCG) vaccine, an attenuated *Mycobacterium bovis,* has been extensively used in national vaccination programs, as it confers cross-protection from *M. tuberculosis* infection (5). BCG vaccination of newborns and infants prevents disseminated childhood TB and reduces the risk of pulmonary TB by about 50% (6). Even though the BCG vaccine has been in use for more than 90 years, with proven safety, its efficacy is still controversial (7). BCG vaccination has shown clear protection in children, but in adults its effects have been inconsistent (8). Many countries initiated national BCG vaccination in the middle of the twentieth century with variable levels of coverage using different BCG strains (9), number of doses, and delivery method (10). As the prevalence of TB decreased, countries like France, Germany, and Spain stopped mass vaccination of children and moved to vaccinate only individuals at high risk. Other countries like Russia, Portugal, and China have continued national BCG vaccination to date. Some countries never established national universal BCG vaccination, including the United States and Italy, and only target high-risk individuals (10)

For many decades, the innate immune response was thought to be hardwired and unable to adapt and "learn" from previous exposure to a pathogen. In the last ten years several studies demonstrated that the priming or "training" of the innate immune system is an ancient response observed in evolutionary distant organisms including plants (11), insects (12), and humans (13). Trained immunity, defined as the enhancement in innate immune responses to subsequent infections, is achieved through epigenetic and metabolic programming of immune cells that allow them to mount a stronger response to pathogens and to activate adaptive

responses more efficiently (14). Trained immunity can confer broad protection that is not pathogen-specific. For example, BCG vaccination is approved as a treatment for cancer of the bladder, and destruction of cancer cells has been shown to be mediated by trained immunity (15). Furthermore, BCG vaccination has been shown to elicit long-lasting innate immune responses, beyond those specific to mycobacterium (16), and to modify hematopoietic stem cells, resulting in epigenetically modified macrophages that provide significantly better protection against virulent *M. tuberculosis* infection than naïve macrophages. (17).

There is also ample epidemiological evidence that BCG vaccination has broad protective effects that are not specific to *M. tuberculosis* infection. For example, in 1927, Swedish children who received BCG vaccination at birth had a mortality rate almost threefold lower than unvaccinated children that could not be explained by TB infection, and thus early on, it was suggested that the very low mortality among BCG vaccinated children may be caused by nonspecific immunity (18). In West Africa, a BCG vaccination scar and a positive tuberculin reaction were associated with better survival during early childhood in an area with high mortality; this was not observed with other childhood vaccines (19). A general reduction in neonatal mortality was also reported in children from Guinea-Bissau, mainly due to fewer cases of neonatal sepsis, respiratory infection, and fever (20). The BCG vaccine appears to confer broad enhanced immunity to respiratory infections, as infants from Guinea-Bissau with acute viral infections of the lower respiratory tract were more likely to not have received BCG vaccination than matched controls (21). In Spain, hospitalizations due to respiratory infections in 0-14 year-old children not attributable to TB, were significantly lower in BCG-vaccinated compared to non-BCG-vaccinated children (22). The observation that this protection was still present in 14 year-old children suggests that the broad protective effect of BCG can be long-lasting. Taken together, our current understanding of broad immune protection mediated by trained immunity and the epidemiologic evidence of long-lasting protection from viral infections of the respiratory tract, conferred by BCG vaccination, offers a rational biological basis for the potential protective effect of BCG vaccination from severe COVID-19.

Considering the cross-protection reported for BCG vaccination on viral respiratory infections, recent publications have proposed that BCG vaccination could have protective

effects against COVID-19 infection (23), (24), (25). These publications, however, do not include statistical analysis, and the World Health Organization has cautioned about the lack of research regarding BCG vaccination against COVID-19 infection (26). In view of the growing interest to assess the plausible association between BCG vaccination and protection from severe COVID-19, we assessed available global data on BCG and COVID-19 to investigate the hypothesis that countries without a national BCG vaccination program would have greater COVID-19 mortality than countries that have a program. We attempted to control for potential confounding variables among countries such as, level of urbanization, population density, age classes, access to health, income, education, and stage and size of the COVID-19 epidemic.

Methods

Broad Analysis

We collected COVID-19 mortality data by country, considering that numbers of deaths may be more reliable than the numbers of cases, since case numbers are greatly influenced by the intensity of diagnostic efforts, criteria for testing, number of asymptomatic cases, and availability and sensitivity of diagnostic tests (27). Number of deaths are also a good proxy of epidemic size during explosive epidemics, considering that often the number of cases is underreported due to overwhelmed and unprepared health systems (i.e., *surveillance fatigue*) (28). We developed statistics tests (i.e., ANOVA, t-test, linear regression, normality probability) (29) to determine linkages between use of BCG vaccine and number of COVID-19 deaths (α=0.05). BCG vaccination data were collected at the country level based on policy of vaccination (i.e., current, interrupted, never) (10) and the mean and median percentage of vaccination coverage during the periods 1980-1985 and 1980-2018 (30). COVID-19-related deaths were collected until April 23, 2020 and were standardized by population and stage of the epidemic (31). Independent (i.e., with vs. without BCG vaccination, policy of BCG vaccination in place, percentage of vaccine coverage) and dependent variables (i.e., mean, median, and maximum deaths per million) were compared using data at specific times of each country's epidemic since the first death (e.g., first month, week-three, middle, full period). This

design allowed fair comparisons between countries at different epidemic stage and of different population size (Supplementary Data).

Refined Analysis

The hypothesis that countries without a national BCG vaccination program would have greater COVID-19 mortality in adult populations than countries that have a program was investigated at the global level and filtered by social conditions. Analyses were performed initially for countries with BCG vaccination data, ≥1 M inhabitants, and COVID-19-related deaths. We focused on social variables as potential confounding factors, excluding climatic conditions in view of the lack of evidence for temperature-dependence of the COVID-19 epidemic (32). Potential confounding variables were assessed based on access to health and education services and income (i.e., Human Development Index) (33), population size (34), human density (35), urbanization (36), and age of the population (37). For a fair comparison between countries, and after a preliminary evaluation of association (Table S1), BCG vaccination and COVID-19 deaths assessments were conducted for countries with at least one death per million of inhabitants, ≥15% population with an age of 65 years or more, >60% of population living in urban areas, <300 inhabitants per km^2, and a HDI >0.7. These inclusion criteria allowed comparisons of countries with similar social conditions to mitigated effects of confounding factors (Table S1). Considering the size and social disparities of the United States, analyses were also performed considering the United States as a country, and separately by state.

The COVID-19 pandemic arrived in the Americas by air traffic. An epidemiological analysis at a country level does not consider the intense clustering of cases in States with large metropolitan areas. Thus, we decided to compare COVID-19 mortality in US States without BCG vaccination that have a high number of confirmed cases (more than 20,000 by 4/20/2020) with those that were the main points of entry in Mexico and Brazil, as these two countries have current BCG vaccination programs. Evaluations were restricted to mortality 25 days after the first COVID-19 related death was registered. East and West Germany followed different BCG vaccination schemes before the reunification in 1990. In West Germany, infants were

vaccinated between 1961-1998, so that those 22-59 years old today were vaccinated. In East Germany, infants and 15 year-old teenagers with a negative skin test were vaccinated from 1951-1975; as a result, those 45-84 years old today received at least one dose of BCG. German states (38) was compared (see Supplementary Data). Most of the mortality in Germany (95%) is observed in older individuals (60 years old or more) (39). We explored whether the broader range in BCG vaccination in eastern states of older individuals could reduce the mortality from COVID-19.

Results

Coarse analysis. Global analysis of COVID-19 mortality revealed striking differences between countries (Figs. 1A, S1; Tables S2-S4), with positive association between human development index (HDI) and COVID-19 mortality (Figs. 1B, S2). The global map of vaccination policy suggested inverse association, with countries with stronger BCG vaccination policy having lower COVID-19 mortality (Fig. 1C). Coarse analysis revealed a consistent link between BCG vaccination and COVID-19 mortality under different scenarios of data curation (Tables S2-S4). For example, countries with a stronger BCG vaccination policy (i.e., current, interrupted, or never) had significantly lower COVID-19 deaths/million (1 M) (Table S2; Fig. 2A). More broadly, countries with current vaccination had lower deaths as compared to countries with lack of, or interrupted BCG vaccination (Table S3). Similarly, the percentage of BCG coverage was negatively associated with COVID-19 deaths/1 M (Table S4). The association was consistently supported by the coarse-level analysis when considering the United States as a country or by analyzing individual states, and when correcting by the stage of the epidemic (Tables S2-S4).

Filtered analysis. When the effects of potentially confounding factors on the dependent variables was mitigated by including only countries with at least one death per million of inhabitants, ≥15% population with an age of 65 years or more, >60% of population living in urban areas, <300 inhabitants per km^2, and a HDI >0.7 (Table S1), we were left with 22 socially similar countries. The control of confounding variables reduced the overall significant effect and association between BCG and COVID-19 deaths (i.e., linear models and ANOVA: coarse=100% significant analysis vs. refined=23%; t-test: coarse=92% significant analysis vs. refined=37%;

Tables S2-S4). Nevertheless, a significant association and effect was still detected for several comparisons controlling for social conditions and stage of the epidemic by country (Tables S2-S4). For example, type of BCG policy (i.e., current, interrupted, and never vaccination) had a significant effect on COVID-19 deaths/1 M (Fig. 2B; Table S2), with a stronger policy being associated with lower COVD-19 mortality. Additionally, countries with current vaccination had lower deaths as compared with countries with lack of or interrupted BCG vaccination (Fig. 2C; Table S3). Similarly, mean BCG coverage (%) was negatively associated with the maximum value of COVID-19 deaths/1 M reported by country during the first month of the pandemic (Fig. 2D; Table S4).

Arrival of the Pandemic to the Americas. The COVID-19 pandemic arrived in the Americas by air traffic, and regions with high number of international flights from Europe have been the most affected. Thus, we decided to compare COVID-19 mortality in States from the United States without BCG vaccination with those that were the main points of entry in Mexico and Brazil, as these two countries have current BCG vaccination programs. We found that COVID-19 mortality in the states of New York, Illinois, Alabama, and Florida (unvaccinated) was significantly higher ($t(237)=14.274$, $p<0.001$) than states from BCG-vaccinated countries (Pernambuco, Rio de Janeiro, and Sao Paulo in Brazil; Mexico State and Mexico City in Mexico) (Fig. 3A, left panel). This is remarkable, considering that the three States from Latin America have much higher population density than the North American states analyzed, including New York (Fig. 3A, right panel). Because of the differences in latitude, one can envision that differences in climate could be responsible for the lower mortality in southern countries. However, one must consider that the average temperature in the month of March in Mexico City (62.2°F) and Sao Paulo (64.4 °F) is lower than in Florida (69.9 °F) or Louisiana (66.3°F), and that there is preliminary evidence for lack of temperature-dependence for the COVID-19 epidemic, based on data from China (32).

The Pandemic in Europe. We also found broad differences in COVID-19 mortality within Europe. Germany provides a unique opportunity to compare the potential effect of age of BCG vaccination on susceptibility to COVID-19, as, before the unification, East and West Germany followed different vaccination schemes. In West Germany those 22-59 years old today were vaccinated, while in East Germany those 45-84 years old today received at least one dose of BCG (Fig. 3A-B). A comparison of these two regions revealed that the average COVID-19 mortality rate in western German states (40.5 per million) was 2.9-fold higher than in eastern states (14.2 per million) (Fig. 3B-C). Similarly, the mean mortality in Western Europe was 9.92 times higher than in Eastern Europe ($t(11)=-2.592$, $p<0.025$) (Fig. 4A), where countries have active universal BCG vaccination programs (Fig. 4B).

Western Europe has a complex history of BCG vaccination, ranging from Finland, which had a universal vaccination program for 65 years initiated in 1941, to other countries like Italy, Belgium and the Netherlands, which have never had universal BCG vaccination (Fig. 4B). To give these differences a quantitative value, a BCG vaccination index was developed by multiplying the age of the older group that was vaccinated (because COVID-19 mortality increases by age) by the number of years that a program was maintained. To adjust the index to a scale from 0 to 1, the product was divided by the score of countries with 75 years of continuous vaccination (75 x 75 = 5,625) Fig. 4C. We found a significant ($r^2=0.49$, $p<0.00001$) negative correlation between BCG index and COVID-19 mortality in European countries that administer the BCG vaccine to infants by intradermal injection (Fig. 4D). In this analysis, the United Kingdom was excluded because it administered the vaccine to older children (12-13 years old) (10), and France because it administered the vaccine to infants and young children going to daycare, or to children of school age (40). We noted that COVID-19 mortality was higher in the United Kingdom and France compared to Germany, Scandinavia, or Eastern European countries (Fig. 4A). Finally, to try to control for other confounding factors that could affect COVID-19 mortality, we repeated the analysis including only those European countries that are socially similar (see "*filtered analysis*" section) and normalized the time of arrival of the pandemic by comparing the mortality during the first 30 days after the first COVID-19 death was reported in each country. A highly significant linear correlation was found between the

BCG index and mortality during the first month of the pandemic (R^2 = 0.88; P = $8x10^{-7}$) (Fig. 4E); indicating that every 10% increase in the BCG index is associated with a 10.4% reduction in COVID-19 mortality.

Discussion

The consistent association between BCG vaccination and reduced severity of COVID-19 observed in these and other epidemiological explorations is remarkable, but not sufficient to establish causality between BCG vaccination and protection from severe COVID-19. Randomized clinical trials, such as those ongoing in Holland (41) and Australia (42), in which health workers are administered either the BCG vaccine or a placebo saline injection, will determine the extent to which BCG vaccination in adults confers protection from COVID-19. BCG is usually not administered to adults due to the lack of consistent TB protection (8). However, it is unclear if this will also be the case for BCG enhancement of broad innate immunity in the lungs. There is limited information on the safety of administering BCG to senior persons, since BCG is a vaccine based on a live attenuated mycobacterium that should not be administered to immunocompromised individuals (43). *M. tuberculosis* infection can remain latent for decades and reactivate in the elderly when a senescent immune system loses the ability to contain the infection (44). A small study found that vaccination of adults $\geq$ 65 years old with BCG prevented acute upper respiratory tract infections (45), and there is an active clinical trial vaccinating adults >65 years with BCG to boost immunity (46).

Most striking, is that COVID-19-related deaths are significantly higher in countries with higher quality of life (Fig. 1), contradicting the expected rates of mortality in countries with improved health care systems. The augmented COVID-19 mortality in developed countries when compared to developing countries remained consistent even after correcting for social confounding factors and age. There are several important social differences between eastern and western German states, such as lower GDP in former East Germany, and higher percentage of population 65 or older in eastern states (24%) than in western ones (21%) (38), but it is hard to envision how these factors could decrease their risk of COVID-19 fatality in eastern German states. One should consider that the difference in mortality could also be explained, at least in

part, by the lower population density in East Germany (154/Km^2) than in West Germany (282/Km^2). This variable is difficult to control, as there is great heterogeneity in population density even within each state.

The lack of apparent protection observed in the United Kingdom and France, where BCG vaccination was administered to older children, suggests that either trained immunity observed when infants are vaccinated is no longer achieved in older children, or it may be of shorter duration. It is also possible that the BCG strains used, or the administration route, also affect the innate immune response to vaccination. Considering the remarkable dissemination capacity and the mortality rates of COVID-19, vaccination capable of conferring even transient protection (e.g., 6 - 12 months) may be useful in individuals at high risk, such as health workers, first responders, and police officers, or those with pre-existing conditions such as obesity, diabetes, or cardiovascular disease. Similarly, even improved unspecific cellular immunity through BCG vaccination in vulnerable age groups could ameliorate severe COVID-19. Temporary induced trained immunity could buy time until specific vaccines and/or effective treatments against Severe Acute Respiratory Syndrome- coronavirus 2 (SARS-CoV-2) infections become available.

If the BCG protection hypothesis holds true, it would have great implications for regions with ongoing universal vaccination programs, including most developing countries, as they may experience lower morbidity and mortality during the pandemic than in Europe and North America. We found that beyond BCG vaccination protection, the year in which BCG vaccination was introduced and the level of coverage may play a key role in the reduction of COVID-19 severity. For example, in many Latin American countries, universal vaccination was introduced in the mid 1960's, suggesting that individuals ≥55 yrs would not be vaccinated and, in turn, represent a vulnerable segment of the population regarding COVID-19. Similarly, individuals born in years with low BCG vaccine coverage would be populations at risk. The proposed BCG Index should be corrected by the average proportion of vaccine coverage, and this would be very important in countries with historically low vaccination rates. Most Asian countries have active universal BCG vaccination programs. If BCG is conferring some basal level of protection from COVID-19, it is possible that some of the social distancing roll-back strategies taken by

Asian countries, in order to restart their economies, may not be effective in North America and Western European countries, and could result in a second wave of infections.

Our understanding of the biology of innate immune training is in its infancy (14). Little is known regarding the capacity of BCG vaccine to confer broad immune enhancement and the functional correlates of protection. Our inability to confirm the null hypothesis of no effect of BCG on COVID-19 mortality could be explained by cross-protection mediated by BCG vaccination. We note, however, that the data used in this epidemiological study has important sampling bias, and that the statistical signal detected at the country level may not explain COVID-19 mortality at the local level. The possibility that a single exposure to an attenuated pathogen during infancy could result in life-long enhancement in immune surveillance would be remarkable, but the available epidemiological data, in the absence of direct evidence from clinical trials, is not sufficient to recommend the use of BCG for the control and prevention of COVID-19 or other emerging infectious diseases.

Funding

This work was supported by the Intramural Research Program of the Division of Intramural Research Z01AI000947, National Institute of Allergy and Infectious Diseases (NIAID), NIH, and Virginia Tech startup funds for LEE.

Acknowledgments

The authors gratefully acknowledge Asher Kantor and Mark Johnson for editorial assistance and Maiana Castaneda-Guzman and Ana Beatriz Barletta Ferreira for assistance on data collection and handling.

Figures

Figure 1. COVID-19 mortality, human development, and BCG vaccination policy by country. A) Map showing the COVID-19 mortality per million inhabitants in countries worldwide. D COVID-19-related deaths per country per 1,000,000 inhabitants denoting countries with low (yellow) to high (red) mortality. **B)** COVID-19 mortality per million inhabitants (log) vs. Human Developing Index (HID) in different countries worldwide. **C)** Map showing the BCG vaccination policy in countries that currently have universal BCG vaccination program (Current), countries with interrupted BCG vaccination programs (Interrupted), and countries that never implemented a universal vaccination program (Never). Countries without information appear in white.

Figure 2. Linkage between COVID-19 mortality and BCG vaccination. A) Coarse analysis of COVID-19 mortality per million inhabitants in countries with current, interrupted or that never had BCG vaccination programs. **B)** Filtered analysis of COVID-19 mortality per million inhabitants in countries with current, interrupted or that never had BCG vaccination programs and similar social, economic, and epidemic stage conditions. **C)** Filtered analysis of COVID-19 mortality per million inhabitants in countries with current vs. interrupted or that never had BCG vaccination programs, including only countries with similar social, economic, and epidemic stage conditions. **D)** Negative association between percentage of vaccination coverage (mean) between 1980 and 2018, as a proxy of population protection, and maximum COVID 19 deaths per million inhabitants registered by country in a day, as a proxy of COVID-19 severity. Full list of analysis available in Supplementary Tables S2-S4.

Figure 3. COVID-19 mortality in comparable regions that have had different BCG vaccination policies. A) COVID-19 mortality by time in populous North and South American States. COVID-19 mortality per 10 million inhabitants in a 3-day centered average. Time adjusted according to the day with the first death in each region as day 1, up to 25 days of the epidemic. Table shows population density and COVID-19 mortality by day 25 of the epidemic for each region. Regions that have had BCG vaccination (blue) had lower mortality than regions without BCG vaccination (red; r^2=0.84, p<0.001; t(237)=14.274, p<0.001). **B)** Estimated age range of people that received BCG vaccination in East and West Germany. **C)** Map illustrating the regions of East and West Germany included in the analysis. **D)** Mean COVID-19 mortality in East Germany was lower than mortality in West Germany (t(11)=-2.592, p=0.025).

Figure 4. Variation in COVID-19 mortality and BCG vaccination policy in different European countries. A) Map illustrating COVID-19 deaths per million inhabitants in European countries. **B)** Map illustrating BCG vaccination policy in European countries that currently have universal BCG vaccination program (Current), countries that interrupted in the past a BCG vaccination program (Interrupted), and countries and never implemented a universal vaccination program (Never). **C)** BCG Index = (age of oldest vaccinated cohort × total number of years of vaccination campaign) divided by the value for countries with 75 years of continuous vaccination (75 X 75 = 5625) and corrected by the mean BCG vaccine coverage. **D)** Correlation between BCG Index and COVID-19 mortality per million inhabitants and in European countries with different BCG vaccination policy. **E)** Correlation between BCG Index and COVID-19 mortality per million inhabitants during the first month of the pandemic in socially similar European countries with different BCG vaccination policy.

References

1. D. Artis, H. Spits, The biology of innate lymphoid cells. *Nature* **517**, 293-301 (2015).

2. J. Chan, J. Flynn, The immunological aspects of latency in tuberculosis. *Clin Immunol* **110**, 2-12 (2004).

3. M. Rossouw, H. J. Nel, G. S. Cooke, P. D. van Helden, E. G. Hoal, Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. *Lancet* **361**, 1871-1872 (2003).

4. J. L. Flynn *et al.*, An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. *J Exp Med* **178**, 2249-2254 (1993).

5. C. Dye, Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered. *J R Soc Interface* **10**, 20130365 (2013).

6. G. A. Colditz *et al.*, The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics* **96**, 29-35 (1995).

7. S. Luca, T. Mihaescu, History of BCG Vaccine. *Maedica (Buchar)* **8**, 53-58 (2013).

8. P. Mangtani *et al.*, Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis* **58**, 470-480 (2014).

9. WHO (2020) BCG immunization coverage estimates by country. p https://apps.who.int/gho/data/node.main.A830?lang=en.

10. A. Zwerling *et al.*, The BCG World Atlas: a database of global BCG vaccination policies and practices. *PLoS Med* **8**, e1001012 (2011).

11. M. Muthamilarasan, M. Prasad, Plant innate immunity: an updated insight into defense mechanism. *J Biosci* **38**, 433-449 (2013).

12. J. Rodrigues, F. A. Brayner, L. C. Alves, R. Dixit, C. Barillas-Mury, Hemocyte differentiation mediates innate immune memory in Anopheles gambiae mosquitoes. *Science* **329**, 1353-1355 (2010).

13. W. J. M. Mulder, J. Ochando, L. A. B. Joosten, Z. A. Fayad, M. G. Netea, Therapeutic targeting of trained immunity. *Nat Rev Drug Discov* **18**, 553-566 (2019).

14. M. G. Netea, E. Latz, K. H. Mills, L. A. O'Neill, Innate immune memory: a paradigm shift in understanding host defense. *Nat Immunol* **16**, 675-679 (2015).

15. K. Buffen *et al.*, Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. *PLoS Pathog* **10**, e1004485 (2014).

16. J. Kleinnijenhuis *et al.*, Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. *J Innate Immun* **6**, 152-158 (2014).

17. E. Kaufmann *et al.*, BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. *Cell* **172**, 176-190 e119 (2018).

18. C. Näslund, Resultats des experiences de vaccination par le BCG poursuivies dans le Norrbotten (Suède) (Septembre 1927–Décembre 1931). *Vaccination Preventative de Tuberculose, Rapports et Documents. Paris: Institut Pasteur* (1932).

19. M. L. Garly *et al.*, BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? *Vaccine* **21**, 2782-2790 (2003).

20. P. Aaby *et al.*, Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? *J Infect Dis* **204**, 245-252 (2011).

21. L. G. Stensballe *et al.*, Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. *Vaccine* **23**, 1251-1257 (2005).

22. M. J. de Castro, J. Pardo-Seco, F. Martinon-Torres, Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. *Clin Infect Dis* **60**, 1611-1619 (2015).

23. S. IK., BCG is a good immunotherapeutic agent for viral and autoimmune diseases: Is it a new weapon against coronavirus (COVID-19)? . *Electron J Gen Med* **17** (2020).

24. S. J. Hegarty PK, Giannarini G, Dinardo AR, Kamat AM. , COVID-19 and Bacillus Calmette-Guérin: What is the Link? *Eur Assoc Urol* **in press** (2020).

25. P. R. de Freitas e Silva R, What are the factors influencing the COVID-19 outbreak in Latin America? . *Travel Med Infect Dis* **In press.** (2020).

26. WHO (2020) Bacille Calmette-Guérin (BCG) vaccination and COVID-19. . pp https://www.who.int/news-room/commentaries/detail/bacille-calmette-guérin-(bcg)-vaccination-and-covid-19.

27. Y. Fang *et al.* (2020) Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. in *Radiology*, pp 2-8.

28. D. Romero-Alvarez, A. T. Peterson, L. E. Escobar (2017) Surveillance fatigue (*fatigatio vigilantiae*) during epidemics. in *Revista chilena de Infectología*, pp 289-292.

29. N. J. Gotelli, A. M. Ellison (2013) A Primer of Ecological Statistics. (Sinauer Associates, Sunderland).

30. WHO (2019) Baccille Calmette Guérin vaccine. in *Reported estimates of BCG coverage*.

31. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 10.1016/S1473-3099(20)30120-1 (2020).

32. A. I. Jamil T, Gojobori T, Duarte CM. (2020) No evidence for temperature-dependence of the COVID-19 epidemic. (medRxiv), https://www.medrxiv.org/content/10.1101/2020.1103.1129.20046706v20046702.

33. United Nations Development Program (2019) Human Development Data (1990-2018). in *Human Development Reports*. http://hdr.undp.org/en/data

34. Wold Bank (2018) Population. in *World Development Indicators 2.1*.

35. Wold Bank (2019) Population density (people per sq. km of land area). in *World Bank Open Data*.

36. Wold Bank (2019) Urban population (% of total population). in *World Bank Open Data*.

37. Wold Bank (2018) Population dynamics: Population age composition. in *World Development Indicators 2.1*.

38. Federal Statistical Office of Germany (2016) Older People in Germany and the EU. https://www.bmfsfj.de/blob/113952/83dbe067b083c7e8475309a88da89721/aeltere-menschen-in-deutschland-und-in-der-eu-englisch-data.pdf

39 Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-15-en.pdf

40. French Government (1950) BCG Vaccination Law. https://www.legifrance.gouv.fr/jo_pdf.do?id=JORFTEXT000000705041&pageCourante=00198

41. NLM Vaccine Trials (2020) Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA). p https://clinicaltrials.gov/ct2/show/NCT04328441.

42. NLM Vaccine Trials (2020) BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE). https://clinicaltrials.gov/ct2/show/NCT04327206.

43. A. C. Hesseling *et al.*, The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. *Vaccine* **25**, 14-18 (2007).

44. S. Rajagopalan, Tuberculosis and aging: a global health problem. *Clin Infect Dis* **33**, 1034-1039 (2001).

45. Wardhana, E. A. Datau, A. Sultana, V. V. Mandang, E. Jim, The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. *Acta Med Indones* **43**, 185-190 (2011).

46. NLM Vaccine Trials (2017) Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly (ACTIVATE). https://clinicaltrials.gov/ct2/show/record/NCT03296423


A
Deaths/1M
400 - 1200
200 - 399
100 - 199
20 - 99
0 - 19
0 3,000
Km


B
$y = -6.6 + 10 \times x$, $R^2 = 0.57$, $p = 3x10^{-42}$
5.0
2.5
0.0
-2.5
Death/Million (log)
0.4
0.6
0.8
HDI


C
BCG Policy
Current
Interrupted
Never
0 3,000
Km


A
BCG Policy
Deaths / Million (log)
5
0
-5
Current
Interrupred
Never
B
BCG Policy
Deaths / Million (log)
8
6
4
2
0
Current
Interrupred
Never
C
BCG Policy
Deaths / Million (log)
6
4
2
0
Italy
Spain
France
United Kingdom
Switzerland
Sweden
United States
Portugal
Denmark
Germany
Estonia
Canada
Norway
Finland
Lithuania
Hungary
Greece
Bulgaria
Poland
Latvia
Ukraine
Current
Never and Interrupted
D
Deaths Max/Million
20
15
10
5
0
$y = 7.8 + -0.065 \times x$, $R^2 = 0.27$, $p = 0.02$
Spain
Italy
Sweden
United Kingdom
Switzerland
Germany
Canada
United States
Australia
Portugal
Denmark
Norway
Lithuania
Greece
Finland
France
Poland
Bulgaria
Ukraine
Hungary
0
25
50
75
100
BCG Mean coverage

A



Region	Pop/km^2	Deaths/M
NY State	159	172
Louisiana	34	160
Illinois	88	34
Alabama	36	30
Florida	155	26
Pernambuco	97	19
S. Paulo St.	185	11
Rio Janeiro St.	394	9
Mex St. + City	1053	6

B



C

D







C

$$\textit{BCG index} = \left(\frac{\textit{Age of older vaccinated cohort} \times \textit{Total years of universal vaccination}}{5{,}625} \right) \times \textit{vaccine coverage}$$